CARsgen Therapeutics-B (02171): First patient dosed in China Phase I registrational clinical trial of CT1190B

Zhito Finance APP News, CARsgen Therapeutics-B (02171) announced that CT1190B, a universal CAR-T cell product targeting CD19/CD20, has completed first patient infusion in its Phase I registrational clinical trial in China, for the treatment of patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) who have failed at least two lines of standard therapy. The IIT study results of CT1190B have been presented as a poster at the 2026 European Hematology Association (EHA) Annual Congress.